Adstiladrin Market Report 2026

Adstiladrin Market Overview

• The Adstiladrin market growth in the historic period has been driven by limitations of bcg therapy, advances in gene delivery systems • Market expansion is supported by expansion of gene therapy pipelines, increasing oncology precision medicine adoption • Growth Driver: Rising Incidence Of Bladder Cancer Fuels Adstiladrin Market Growth • Market Trend: Adenovirus-Based Gene Therapy Advancements Elevating Treatment Outcomes In Bladder Cancer Care • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Adstiladrin Market?

Adstiladrin is a gene therapy medication designed to treat high-risk non-muscle-invasive bladder cancer (NMIBC) that does not respond to Bacillus Calmette-Guérin (BCG) therapy. It contains nadofaragene firadenovec, a non-replicating adenoviral vector that delivers the interferon alfa-2b gene directly to bladder cells. This process stimulates the local production of interferon alfa-2b, a protein with antitumor properties, enhancing the immune system's ability to target cancer cells. The main types of indication for adstiladrin include high-risk non-muscle-invasive bladder cancer (NMIBC) and other bladder cancer variants. High-risk non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor is confined to the inner lining of the bladder and has a high potential for recurrence or progression. It is distributed through various channels, including hospitals and clinics, retail pharmacies, and specialty pharmacies, and is used by both adults and geriatrics.

What Is The Adstiladrin Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of gene therapy pipelines, increasing oncology precision medicine adoption, higher investment in viral vector manufacturing, improved long term efficacy data, growing awareness of nmibc treatment options. Major trends in the forecast period include rising adoption of gene therapy in oncology, focus on bladder cancer immunotherapy, growing use of viral vector technologies, shift toward localized cancer treatments, increasing demand for bcg unresponsive therapies.

Global Adstiladrin Market Segmentation

1) By Indication: High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC), Other Bladder Cancer Variants 2) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Adstiladrin Market?

The rising incidence of bladder cancer is expected to drive the growth of the adstiladrin market going forward. Bladder cancer is a type of cancer that begins in the cells of the bladder, the hollow organ in the lower abdomen that stores urine. Bladder cancer is rising because of smoking, an aging population, environmental toxins, chronic bladder conditions, and better diagnostic methods. Adstiladrin is needed for bladder cancer treatment because it offers an effective option for high-risk non-muscle-invasive bladder cancer (NMIBC) patients unresponsive to BCG therapy, reducing the need for radical surgery. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of urinary bladder cancer cases increased to 83,190 compared 82,290 in 2023, reflecting a growth of 1.09%. Therefore, the rising incidence of bladder cancer is driving the growth of the adstiladrin industry. The rising healthcare expenditure is expected to propel the growth of the adstiladrin market going forward. Healthcare expenditure refers to the total amount of money spent by individuals, governments, and organizations on healthcare services, products, and infrastructure, including preventive, curative, rehabilitative, and palliative care. Healthcare expenditure is rising due to factors like aging populations, the prevalence of chronic diseases, advancements in medical technology, increased demand for healthcare services, and rising drug and treatment costs. Increased healthcare expenditure enables greater investment in advanced therapies like Adstiladrin, improving access to innovative treatments for high-risk bladder cancer patients. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023.Therefore, the rising healthcare expenditure is driving the adstiladrin industry.

Key Players In The Global Adstiladrin Market

Major companies operating in the adstiladrin market are Ferring Pharmaceuticals Inc.

Global Adstiladrin Market Trends and Insights

Major companies operating in the adstiladrin market are focusing on developing innovative products, such as adenovirus vector-based gene therapies, to improve treatment outcomes. Adenovirus vector-based gene therapy uses modified adenoviruses as delivery vehicles to transport therapeutic genes into target cells, enabling the treatment of genetic disorders or diseases. or instance, in 2024, Ferring Pharmaceuticals, a Switzerland-based provider of urology and oncology therapies, announced the commercial launch of ADSTILADRIN (nadofaragene firadenovec-vncg). Its key features include intravesical administration via catheter directly into the bladder every three months, a gene construct encoding interferon-alpha 2b that turns bladder wall cells into “interferon microfactories,” a favorable safety profile with mostly low-grade adverse events, and demonstrated durable complete responses in BCG-unresponsive NMIBC patients.

Regional Insights

North America was the largest region in the adstiladrin market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Adstiladrin Market?

The adstiladrin market consists of sales of gene therapy medications, adenoviral vectors, immune checkpoint inhibitors and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adstiladrin Market Report 2026?

The adstiladrin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adstiladrin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.